Bot Image

ProstatID: A Smarter, Non-Invasive Approach to Prostate Cancer Detection Prostate cancer is one of the most common types of cancer among men, and early detection is key to improving treatment outcomes and survival rates. Traditionally, detecting prostate cancer has relied on blood tests, such as the prostate-specific antigen (PSA) test, and hormone tests, which, while valuable, have limitations that can lead to unnecessary procedures or missed diagnoses. Enter Bot Image’s ProstatID, a groundbreaking software solution that transforms the way prostate cancer is diagnosed, offering a non-invasive, precise, and patient-friendly alternative. DOTmed.com, Inc Bot Image #ai #medicalequipment

Today's next #RSNA24 Doc Talk session sponsored by partner sponsor, Bot Image, starts at 2 PM! Hear from Randy Jones D.E., Ph.D. on the newest standards in care for Prostate Cancer. Hope to see you there! Download a calendar invite: Apple: https://hubs.ly/Q02ZKDBk0 Google: https://hubs.ly/Q02ZKJrt0 Outlook: https://hubs.ly/Q02ZKrPf0 #TeraReconDocTalks #ProstateCare #healthcareinnovation

If you're interested in learning more on how AI is revolutionizing prostate cancer detection, make sure not to miss our Blackford/Calantic AI Theatre session on Monday! Join leading experts as they discuss AI-driven innovations that are improving accuracy and early detection in prostate cancer imaging: 📅 Monday, December 2 | 11:30 - 11:50 AM (CT) 📍 Blackford Booth #4729 🎓 Session: The role of AI in enhancing prostate cancer detection 🤝 Panelists: Randall Jones from Bot Image, Antony Rix from Lucida Medical Ltd Be sure to stop by Booth #4729 to explore how AI is transforming radiology! You can access the full schedule of talks and add the sessions to your calendar here: https://hubs.la/Q02YNphZ0 🌐 #AIMeetsRadiology #Healthcareai #cancerdetection #RSNA2024

Please join us at the Tera Recon Booth on Tuesday Dec 3 @ 2pm as our Founder and CEO Dr. Randall Jones discusses the current challenges and unique opportunities we have in improving Prostate Cancer Detection, Diagnosis and Screening using the worlds most advanced Prostate AI Technology....ProstatID!

Take a moment to read the latest on Mayo's advances in MR Prostate AI technology. Improvements in AUC to 89% with AI and Radiologists combined, reduction in false positives, and eliminating reader variabilities were all noted. Also: the need for tumor location (a second technology was deployed for that task) was identified. I do want to draw some comparisons on where we are commercially available today with our ProstatID technology. We are FDA approved for Detection/Diagnosis/and Non-Contrast Screening Performance @ 93.6% AUROC bpMRI Automated Lesion Detection / Segmentation / Classification. 3D mapping and detailed report We are available through our partnerships with Tera Recon, Blackford Analysis, and as of this week Ferrum Health! We also offer direct to customer a SAAS model via cloud or "On Prem" solution. Delivering a precision-based diagnosis on the front end of the episode of care for Prostate patients can have a profound effect on their journey. Advancements in treatment, active monitoring and surveillance, and the elimination of risks from contrast and random biopsies could drive overall improvements in care and efficiencies for the HCP. I'm highlighting the editor's notes as it notes the market shift from mpMR to bpMR.... the future is here Brian:)! An editorial noted that the study employed the Mayo algorithm on multiparametric MRI exams. Prostate cancer imaging is moving from mpMRI toward biparametric MRI (bpMRI) due to its faster scan times and lack of contrast, and if validated on bpMRI, AI’s impact could be even more dramatic.

With Men's Health month in full swing, the focus on Prostate cancer diagnosis and treatment remains high. 3 new studies just released collectively support changes in today's current pathways and practices. Short read but well worth it!